• Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines 

      Yndestad, Synnøve; Austreid, Eilin; Svanberg, Ida; Knappskog, Stian; Lønning, Per Eystein; Eikesdal, Hans Petter (Peer reviewed; Journal article, 2017-04-17)
      Anthracyclines are key components of human breast cancer chemotherapy. Here, we explored the role of Akt signaling in anthracycline resistance. The antitumor activity of doxorubicin and Akt inhibitor A-443654 alone or ...
    • Adjuvant treatment: the contribution of expression microarrays 

      Lønning, Per Eystein; Chrisanthar, Ranjan; Staalesen, Vidar; Knappskog, Stian; Lillehaug, Johan (Peer reviewed; Journal article, 2007-12-20)
    • Alterations of the retinoblastoma gene in metastatic breast cancer 

      Berge, Elisabet Ognedal; Knappskog, Stian; Lillehaug, Johan; Lønning, Per Eystein (Peer reviewed; Journal article, 2011-01-21)
      Germline mutations affecting the retinoblastoma gene (RB1) predispose to inherited retinoblastomas but also other malignancies, including breast cancer. While somatic RB1 mutations have been detected in different malignancies, ...
    • Assessment of tumor suppressor promoter methylation in healthy individuals 

      Poduval, Deepak; Berge, Elisabet Ognedal; Sichmanovà, Zuzana; Valen, Eivind; Iversen, Gjertrud Titlestad; Minsaas, Laura; Lønning, Per Eystein; Knappskog, Stian (Journal article; Peer reviewed, 2020-08)
      Background The number of tumor suppressor genes for which germline mutations have been linked to cancer risk is steadily increasing. However, while recent reports have linked constitutional normal tissue promoter methylation ...
    • Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate 

      Gansmo, Liv Beathe; Vatten, Lars Johan; Romundstad, Pål Richard; Hveem, Kristian; Ryan, Bríd M.; Harris, Curtis C.; Knappskog, Stian; Lønning, Per Eystein (Peer reviewed; Journal article, 2016-04-12)
      The MDM2 promoter region contains several polymorphisms, some of which have been associated with MDM2 expression, cancer risk and age at cancer onset. del1518 (rs3730485) is an indel polymorphism residing in the MDM2 ...
    • CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer 

      Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Berge, Elisabet Ognedal; Risberg, Terje; Mjaaland, Ingvil; Mæhle, Lovise; Engebretsen, Lars Fredrik; Lillehaug, Johan; Lønning, Per Eystein (Peer reviewed; Journal article, 2008-08-26)
      Background: Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis ...
    • The circular RNome of primary breast cancer 

      Smid, Marcel; Wilting, Saskia M.; Uhr, Katharina; Rodríguez-González, F. Germán; de Weerd, Vanja; Prager-Van der Smissen, Wendy J.C.; van der Vlugt-Daane, Michelle; van Galen, Anne; Nik-Zainal, Serena; Butler, Adam; Martin, Sancha; Davies, Helen R.; Staaf, Johan; van de Vijver, Marc J.; Richardson, Andrea L.; Macgrogan, Gaëtan; Salgado, Roberto; van den Eynden, Gert G.G.M.; Purdie, Colin A.; Thompson, Alastair M.; Caldas, Carlos; Span, Paul N.; Sweep, Fred C.G.J.; Simpson, Peter T.; Lakhani, Sunil R.; Van Laere, Steven; Desmedt, Christine; Paradiso, Angelo; Eyfjord, Jorunn; Broeks, Annegien; Vincent-Salomon, Anne; Futreal, Andrew P.; Knappskog, Stian; King, Tari; Viari, Alain; Børresen-Dale, Anne-Lise; Stunnenberg, Hendrik G.; Stratton, Mike; Foekens, John A.; Sieuwerts, Anieta M.; Martens, John W.M. (Peer reviewed; Journal article, 2019)
      Circular RNAs (circRNAs) are a class of RNAs that is under increasing scrutiny, although their functional roles are debated. We analyzed RNA-seq data of 348 primary breast cancers and developed a method to identify circRNAs ...
    • Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo 

      Knappskog, Stian; Berge, Elisabet Ognedal; Chrisanthar, Ranjan; Geisler, Stephanie; Staalesen, Vidar; Leirvaag, Beryl; Yndestad, Synnøve; de Faveri, Elise Norheim; Karlsen, Bård Ove; Wedge, David C.; Akslen, Lars A.; Lilleng, Peer Kåre; Løkkevik, Erik; Lundgren, Steinar; Østenstad, Bjørn; Risberg, Terje; Mjaaland, Ingvil; Aas, Turid; Lønning, Per Eystein (Peer reviewed; Journal article, 2015-10)
      Chemoresistance is the main obstacle to cancer cure. Contrasting studies focusing on single gene mutations, we hypothesize chemoresistance to be due to inactivation of key pathways affecting cellular mechanisms such as ...
    • ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab 

      Forthun, Rakel Brendsdal; Hovland, Randi; Schuster, Cornelia; Puntervoll, Hanne Eknes; Brodal, Hans Petter; Namløs, Heidi Maria; Aasheim, Lars Birger; Meza, Leonardo Zepeda; Gjertsen, Bjørn Tore; Knappskog, Stian; Straume, Oddbjørn (Peer reviewed; Journal article, 2019)
      Bevacizumab is included in an increasing number of clinical trials. To find biomarkers to predict and monitor treatment response, cancer and angiogenesis relevant mutations in tumour and circulating tumour DNA (ctDNA) were ...
    • Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers 

      Bjørnslett, Merete; Knappskog, Stian; Lønning, Per Eystein; Dørum, Anne (Peer reviewed; Journal article, 2012-10-05)
      Background: While BRCA mutation carriers possess a 20-40% lifetime risk of developing ovarian cancer, knowledge about genetic modifying factors influencing the phenotypic expression remains obscure. We explored the ...
    • Effective treatment of metastatic melanoma by combining MAPK and PI3K signaling pathway inhibitors 

      Aasen, Synnøve Nymark; Parajuli, Himalaya; Hoang, Tuyen; Feng, Zichao; Stokke, Krister; Wang, Jiwei; Roy, Kislay; Bjerkvig, Rolf; Knappskog, Stian; Thorsen, Frits (Peer reviewed; Journal article, 2019-08-29)
      Malignant melanoma is the most aggressive type of skin cancer and is closely associated with the development of brain metastases. Despite aggressive treatment, the prognosis has traditionally been poor, necessitating ...
    • Effects of SNP variants in the 17β-HSD2 and 17β-HSD7 genes and 17β-HSD7 copy number on gene transcript and estradiol levels in breast cancer tissue 

      Straume, Anne Hege; Knappskog, Stian; Lønning, Per Eystein (Peer reviewed; Journal article, 2014-02-18)
      Breast cancers reveal elevated E2 levels compared to plasma and normal breast tissue. Previously, we reported intra-tumour E2 to be negatively correlated to transcription levels of 17β-HSD2 but positively correlated to ...
    • Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC 

      Røsland, Gro Vatne; Dyrstad, Sissel Elisabeth; Tusubira, Deusdedit; Helwa, Reham; Tan, Tuan Zea; Lotsberg, Maria Lie; Pettersen, Ina Katrine Nitschke; Berg, Anna; Kindt, Charlotte; Hoel, Fredrik; Jacobsen, Kristine; Arason, Ari Jon; Engelsen, Agnete; Ditzel, Henrik J.; Lønning, Per Eystein; Krakstad, Camilla; Thiery, Jean Paul; Lorens, James; Knappskog, Stian; Tronstad, Karl Johan (Peer reviewed; Journal article, 2019-06-01)
      Background: Epithelial to mesenchymal transition (EMT) is a well-characterized process of cell plasticity that may involve metabolic rewiring. In cancer, EMT is associated with malignant progression, tumor heterogeneity, ...
    • Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells 

      Ju, Young Seok; Tubio, José M.C.; Mifsud, William; Fu, Beiyuan; Davies, Helen R; Ramakrishna, Manasa; Li, Yilong; Yates, Lucy; Gundem, Gunes; Tarpey, Patrick S.; Behjati, Sam; Papaemmanuil, Elli; Martin, Sancha; Fullam, Anthony; Gerstung, Moritz; Nangalia, Jyoti; Green, Anthony R.; Caldas, Carlos; Borg, Åke; Tutt, Andrew; Michael Lee, Ming Ta; Van't Veer, Laura J.; Tan, Benita K.T.; Aparicio, Samuel; Span, Paul N.; Martens, John W.M.; Knappskog, Stian; Vincent-Salomon, Anne; Børresen-Dale, Anne-Lise; Eyfjörd, Jorunn Erla; Flanagan, Adrienne M.; Foster, Christopher; Neal, David E.; Cooper, Colin; Eeles, Rosalind; Lakhani, Sunil R.; Desmedt, Christine; Thomas, Gilles; Richardson, Andrea L.; Purdie, Colin A.; Thompson, Alastair M.; McDermott, Ultan; Yang, Fengtang; Nik-Zainal, Serena; Campbell, Peter J.; Stratton, Michael R. (Peer reviewed; Journal article, 2015)
      Mitochondrial genomes are separated from the nuclear genome for most of the cell cycle by the nuclear double membrane, intervening cytoplasm, and the mitochondrial double membrane. Despite these physical barriers, we show ...
    • High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function 

      Yndestad, Synnøve; Austreid, Eilin; Knappskog, Stian; Chrisanthar, Ranjan; Lilleng, Peer Kåre; Lønning, Per Eystein; Eikesdal, Hans Petter (Peer reviewed; Journal article, 2017)
      Purpose: PTEN is an important tumor suppressor in breast cancer. Here, we examined the prognostic and predictive value of PTEN and PTEN pseudogene (PTENP1) gene expression in patients with locally advanced breast cancer ...
    • Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers 

      Berge, Elisabet Ognedal; Knappskog, Stian; Geisler, Stephanie; Staalesen, Vidar; Pacal, Marec; Børresen-Dale, Anne-Lise; Puntervoll, Pål; Lillehaug, Johan; Lønning, Per Eystein (Peer reviewed; Journal article, 2010-07-01)
      Background The tumor suppressor pRb plays a key role regulating cell cycle arrest, and disturbances in the RB1 gene have been reported in different cancer forms. However, the literature reports contradictory findings with ...
    • Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases 

      Løes, Inger Marie; Immervoll, Heike; Sorbye, Halfdan; Angelsen, Jon-Helge; Horn, Arild; Knappskog, Stian; Lønning, Per Eystein (Peer reviewed; Journal article, 2016-04)
      We determined prognostic impact of KRAS, BRAF, PIK3CA and TP53 mutation status and mutation heterogeneity among 164 colorectal cancer (CRC) patients undergoing liver resections for metastatic disease. Mutation status was ...
    • Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon 

      Gansmo, Liv Beathe; Knappskog, Stian; Romundstad, Pål Richard; Hveem, Kristian; Vatten, Lars; Lønning, Per Eystein (Peer reviewed; Journal article, 2015-07)
      MDM2 is a key regulator of the p53 tumor suppressor protein and is overexpressed in many human cancers. Two single nucleotide polymorphisms (SNPs) located in the MDM2 intronic promoter (P2) have been found to exert biological ...
    • Influence of p53 isoform expression on survival in high-grade serous ovarian cancers 

      Bischof, Katharina; Knappskog, Stian; Hjelle, Sigrun Margrethe; Stefansson, Ingunn; Woie, Kathrine; Salvesen, Helga; Gjertsen, Bjørn Tore; Bjørge, Line (Peer reviewed; Journal article, 2019-03-27)
      High-grade serous ovarian carcinoma (HGSOC) is characterised by alterations in the p53 pathway. The expression levels of p53 isoforms have been shown to be associated with patient survival in several cancers. This study ...
    • Low expression levels of ATM may substitute for CHEK2 / TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer 

      Knappskog, Stian; Chrisanthar, Ranjan; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Leirvaag, Beryl; Miletic, Hrvoje; Lønning, Per Eystein (Peer reviewed; Journal article, 2012-03-15)
      Introduction: Mutations affecting p53 or its upstream activator Chk2 are associated with resistance to DNAdamaging chemotherapy in breast cancer. ATM (Ataxia Telangiectasia Mutated protein) is the key activator of p53 and ...